Calidi Biotherapeutics Inc (AMEX:CLDI)’s traded shares stood at 2.28 million during the last session, with the company’s beta value hitting 1.20. At the close of trading, the stock’s price was $0.92, to imply an increase of 3.42% or $0.03 in intraday trading. The CLDI share’s 52-week high remains $16.80, putting it -1726.09% down since that peak but still an impressive 20.65% since price per share fell to its 52-week low of $0.73. The company has a valuation of $23.75M, with an average of 1.33 million shares in intraday trading volume over the past 10 days and average of 1.86 million shares over the past 3 months.
Calidi Biotherapeutics Inc (AMEX:CLDI) trade information
After registering a 3.42% upside in the last session, Calidi Biotherapeutics Inc (CLDI) has traded red over the past five days. The 5-day price performance for the stock is -37.68%, and -51.01% over 30 days. With these gigs, the year-to-date price performance is -20.34%. Short interest in Calidi Biotherapeutics Inc (AMEX:CLDI) saw shorts transact 0.59 million shares and set a 0.88 days time to cover.
The extremes give us $2 and $9 for target low and target high price respectively. As such, CLDI has been trading -878.26% off suggested target high and -117.39% from its likely low.
Calidi Biotherapeutics Inc (CLDI) estimates and forecasts
Looking at statistics comparing Calidi Biotherapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Calidi Biotherapeutics Inc (CLDI) shares are -51.27% down over the last 6 months, with its year-to-date growth rate higher than industry average at 74.10% against 16.70%.
CLDI Dividends
Calidi Biotherapeutics Inc has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Calidi Biotherapeutics Inc (AMEX:CLDI)’s Major holders
Calidi Biotherapeutics Inc insiders hold 18.16% of total outstanding shares, with institutional holders owning 2.71% of the shares at 3.31% float percentage. In total, 2.71% institutions holds shares in the company.
We also have Fidelity Extended Market Index Fund and Bridgeway Funds Inc-Ultra Small Company Market Fund as the top two Mutual Funds with the largest holdings of the Calidi Biotherapeutics Inc (CLDI) shares. Going by data provided on Nov 30, 2024 , Fidelity Extended Market Index Fund holds roughly 30.96 shares. This is just over 0.11% of the total shares, with a market valuation of $28364.0. Data from the same date shows that the other fund manager holds a little less at 10.0, or 0.04% of the shares, all valued at about 9161.0.
